Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. (July 2017)

• Record Type: Journal Article
• Authors: Sznol, Mario; Postow, Michael A.; Davies, Marianne J.; Pavlick, Anna C.; Plimack, Elizabeth R.; Shaheen, Montaser; Veloski, Colleen; Robert, Caroline
• Is Part Of: Cancer treatment reviews. Volume 58(2017)
• Page Start: 70
• Page End: 76
• Publication Date: 2017-07
• Subjects: Immune-related adverse events -- Hypophysitis -- Thyroiditis -- Ipilimumab -- Nivolumab -- Melanoma; Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2017.06.002
• Languages: English
• ISSNs: 0305-7372

Abstract

Highlights: High-grade immune-related endocrinopathies occur in ∼1–2% of patients. Can affect thyroid, pituitary, adrenal, gonadal or islet cell function. Endocrinopathies are managed by hormone replacement and are often not reversible. Heightened awareness, routine monitoring, and management can reduce morbidity. Abstract: Agents that modulate immune checkpoint proteins, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death receptor-1 (PD-1), have become a mainstay in cancer treatment. The clinical benefit afforded by immune checkpoint inhibitors can be accompanied by immune-related adverse events (irAE) that affect the skin, gastrointestinal tract, liver, and endocrine system. The types of irAEs associated with immune checkpoint inhibitors are generally consistent across tumor types. Immune-related endocrine events can affect the pituitary, thyroid, and adrenal glands, as well as other downstream target organs. These events are unique when compared with other irAEs because the manifestations are often irreversible. Immune-related endocrine events are typically grade 1/2 in severity and often present with non-specific symptoms, making them difficult to diagnose. The mechanisms underlying immune-related target organ damage in select individuals remain mostly undefined. Management includes close patient monitoring, appropriate laboratory testing for endocrine function, replacement of hormones, and consultation with an endocrinologist when appropriate. An awareness of the symptoms and management of immune-related endocrine events may aid in the safe and appropriate use of immune checkpoint inhibitors in clinical practice.